Opdivo Gets A Melanoma Rejection, But Also An Expansion
This article was originally published in Scrip
A drug that looked like it could do no wrong in the FDA's eyes, Bristol-Myers Squibb Co.'s Opdivo (nivolumab), actually got a rejection from the agency to expand the medicine's use as a single agent for previously untreated patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
You may also be interested in...
Array believes that a zero copay offer for patients will help its newly FDA-approved Mektovi/Braftovi combination stand out from the crowd in melanoma and notes that the regimen also has potential in a larger indication – colon cancer.
New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.
Study finds that Bristol-Myers Squibb's PD-1 inhibitor Opdivo beats the company's CTLA-4 inhibitor Yervoy in Stage III/C or Stage IV melanoma, spurring hopes for ongoing studies in other tumor types.